Print this page    •   Back to Web version of article

International News
Abbott Laboratories Applies to Register Kaletra Tablet With South Africa

April 5, 2006

Abbott Laboratories announced it has applied to register its heat-resistant Kaletra tablet with South Africa. The tablet can be taken at a lower dose, with or without food, and does not require refrigeration. Critics of the company, including Doctors Without Borders, have accused Abbott of being reluctant to register the new Kaletra formulation in developing countries, where a heat-resistant HIV drug would be ideal. The drug was approved in the United States in October, but is not yet approved in Europe -- an endorsement many African countries require before they will accept shipments. Abbott said it expects Kaletra's approval in Europe by midyear.

Back to other news for April 5, 2006

Excerpted from:
Wall Street Journal

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.